• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

November 2, 2022

Study Links COVID-19 Infection With Elevated Risk of Poor Cardiovascular Health, Death

Author(s):

Jill Murphy, Associate Editor

The results showed that these participants were more than 27 times as likely to develop VTE, more than 21.5 times as likely to be diagnosed with heart failure, and 17.5 times as likely to have a stroke.

COVID-19 infection was associated with a subsequent increased risk of poor cardiovascular health and death, specifically among patients whose infection was severe enough to require hospitalization, according to a study by UK Biobank. The risk was found to be highest within the first 30 days of infection, but remained elevated for some time afterwards, according to the study.

A growing body of evidence indicates that individuals who have had been infected with COVID-19 have a greater risk of subsequent cardiovascular problems. However, these studies have been mostly retrospective, included only a few selected health outcomes, and did not consider the severity of the COVID-19 infection, according to the authors of the current study.

The researchers analyzed 53,613 UK Biobank participants, 17,871 of whom were diagnosed with COVID-19 infection between March 2020 and March 2021, and 35,742 who were not. Additionally, the COVID-19 cases included more men, less affluence, and poorer cardiometabolic profiles.

The UK Biobank tracks the health and survival of its participants through medical records and death registration data. Out of the 17,871 COVID-19 cases, 2701 required hospital admission for their infection, 866 were admitted to the hospital for another condition, and 14,304 did not require hospitalization.

Each participant was tracked until a cardiovascular problem arose, they passed away, or until the end of March 2021, providing an average of 141 days of monitoring, ranging from 32 to 395 days.

The cardiovascular outcomes that were considered were heart attack, stroke, heart failure, atrial fibrillation, venous thromboembolism (VTE), pericarditis, death from any cause, death from cardiovascular or ischemic heart disease.

Compared with their matched peers who did not catch the virus, those not requiring hospital admission for COVID-19 infection were nearly 3 times as likely to have a blood clot in a vein and more than 10 times as likely to die of any cause. However, those admitted to the hospital because of COVID-19 had higher risks of all the outcomes considered irrespective of potentially influential demographic and cardiometabolic factors.

The results showed that these participants were more than 27 times as likely to develop VTE, more than 21.5 times as likely to be diagnosed with heart failure, and 17.5 times as likely to have a stroke. Additionally, the risk of newly diagnosed atrial fibrillation was nearly 15 times higher, the risk of pericarditis was nearly 14 times higher, and the risk of heart attack was nearly 10 times as high.

The risk of death from any cause was lower than this population among those who had COVID-19, and the risks of death from cardiovascular or ischemic heart disease were higher. This finding likely parallels the original reason for admission rather than COVID-19 itself, according to the researchers.

Death was higher among people with COVID-19 infection. Those admitted with the virus as a primary reason were 118 times as likely to die as those who did not need hospitalization, whereas those for whom COVID-19 was a secondary diagnosis were 64 times as likely to die.

Further, most cardiovascular disease diagnoses, specifically atrial fibrillation, VTE, pericarditis, and death from any cause occurred within the first 30 days of infection and among those admitted to the hospital for COVID-19 as the primary reason.

However, heightened risk remained beyond 30 days, particularly for heart failure, atrial fibrillation, VTE, pericarditis, and all-cause deaths.

Limitations to the study include that it was observational, so no definitive conclusions can be drawn about cause and effect. Additionally, the analysis did not consider other potentially influential factors, such as the impact of vaccination, new virus variants, or serial infections.

“The long-term sequelae of past COVID-19 exposure is emerging as a dominant public health concern. Our findings highlight the increased cardiovascular risk of individuals with past infection, which are likely to be greater in countries with limited access to vaccination and thus greater population exposure to COVID-19,” the study authors said in a press release. “Such risks are almost entirely confined to those with disease requiring hospitalization and highest in the early (first 30 days) postinfection period.”

REFERENCE

COVID-19 infection linked to heightened risk of poor cardiovascular health/death. EurekAlert! October 24, 2022. Accessed October 25, 2022. https://www.eurekalert.org/news-releases/968662

Related Videos
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com
Older patient with medical health checkup with cardiologist or geriatric doctor. Woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Related Content
Advertisement
Skincare foam -- Image credit: Pavel | stock.adobe.com
Published: May 22nd 2025 | Updated: May 22nd 2025

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis in Adults and Children

Gillian McGovern, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Doctor with human Eye anatomy model with magnifying glass. Eye disease, Refractive Errors, Age Related Macular Degeneration, Cataract, Diabetic Retinopathy, Glaucoma, Amblyopia, Strabismus and Healt - Image credit: Jo Panuwat D | stock.adobe.com
May 22nd 2025

FDA Approves Ranibizumab Injection for Treatment of Diabetic Retinopathy

Kennedy Ferruggia, Assistant Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Adalimumab Medical Injection - Image credit: luchschenF | stock.adobe.com
May 22nd 2025

FDA Grants Interchangeability Designation to Yuflyma, Biosimilar for Humira Across All Approved Doses

Kennedy Ferruggia, Assistant Editor
3D visualization of natural killer cells | Image Credit: © N0X - stock.adobe.com
May 22nd 2025

Distinct NK Cell Subset Predicts Ibrutinib Response and Immune Pathway Activation in CLL

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
Skincare foam -- Image credit: Pavel | stock.adobe.com
Published: May 22nd 2025 | Updated: May 22nd 2025

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis in Adults and Children

Gillian McGovern, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Doctor with human Eye anatomy model with magnifying glass. Eye disease, Refractive Errors, Age Related Macular Degeneration, Cataract, Diabetic Retinopathy, Glaucoma, Amblyopia, Strabismus and Healt - Image credit: Jo Panuwat D | stock.adobe.com
May 22nd 2025

FDA Approves Ranibizumab Injection for Treatment of Diabetic Retinopathy

Kennedy Ferruggia, Assistant Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Adalimumab Medical Injection - Image credit: luchschenF | stock.adobe.com
May 22nd 2025

FDA Grants Interchangeability Designation to Yuflyma, Biosimilar for Humira Across All Approved Doses

Kennedy Ferruggia, Assistant Editor
3D visualization of natural killer cells | Image Credit: © N0X - stock.adobe.com
May 22nd 2025

Distinct NK Cell Subset Predicts Ibrutinib Response and Immune Pathway Activation in CLL

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.